Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (91-100 of 173) with videos related to

Pageof 18
Sort By:
World Journal of Hepatology|May 5, 2015
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapyChantal Dreyer, Marie-Paule Sablin, Mohamed Bouattour, et al.
World Journal of Gastroenterology|September 13, 2012
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-saltsCindy Neuzillet, Olivia Hentic, Benoît Rousseau, et al.
Oncotarget|June 10, 2015
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patientsMaria Serova, Annemilaï Tijeras-Raballand, Célia Dos Santos, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2010
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancerEmmanuel Mitry, Pascal Hammel, Gaël Deplanque, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2005
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cellsMaria Serova, Fabien Calvo, François Lokiec, et al.
Investigational New Drugs|February 20, 2019
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinomaSonia Brun, Firas Bassissi, Cindy Serdjebi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2005
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinomaCatherine Delbaldo, Jean-Yves Pierga, Véronique Dieras, et al.
Investigational New Drugs|February 9, 2013
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancerRuud P M Dings, Joseph I Levine, Susan G Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2009
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental gliomaJean-Sébastien Guillamo, Sophie de Boüard, Samuel Valable, et al.
Biochimie|December 3, 2014
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumorsRamiro Vázquez, Lucile Astorgues-Xerri, Mohamed Bekradda, et al.
Pageof 18

Showing results (91-100 of 173) with videos related to

Sort By:
Pageof 18
World Journal of Hepatology|May 5, 2015
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapyChantal Dreyer, Marie-Paule Sablin, Mohamed Bouattour, et al.
World Journal of Gastroenterology|September 13, 2012
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-saltsCindy Neuzillet, Olivia Hentic, Benoît Rousseau, et al.
Oncotarget|June 10, 2015
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patientsMaria Serova, Annemilaï Tijeras-Raballand, Célia Dos Santos, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2010
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancerEmmanuel Mitry, Pascal Hammel, Gaël Deplanque, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2005
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cellsMaria Serova, Fabien Calvo, François Lokiec, et al.
Investigational New Drugs|February 20, 2019
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinomaSonia Brun, Firas Bassissi, Cindy Serdjebi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2005
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinomaCatherine Delbaldo, Jean-Yves Pierga, Véronique Dieras, et al.
Investigational New Drugs|February 9, 2013
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancerRuud P M Dings, Joseph I Levine, Susan G Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2009
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental gliomaJean-Sébastien Guillamo, Sophie de Boüard, Samuel Valable, et al.
Biochimie|December 3, 2014
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumorsRamiro Vázquez, Lucile Astorgues-Xerri, Mohamed Bekradda, et al.
Pageof 18